FibroGen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FGEN research report →
Companywww.fibrogen.com
FibroGen, Inc. , a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
- CEO
- Thane Wettig
- IPO
- 2014
- Employees
- 225
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $36.69M
- P/E
- 0.17
- P/S
- 3.78
- P/B
- -3.03
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 32.22%
- Op Margin
- -602.06%
- Net Margin
- 2199.13%
- ROE
- -267.30%
- ROIC
- -54.55%
Growth & Income
- Revenue
- $6.44M · -78.26%
- Net Income
- $183.45M · 485.57%
- EPS
- $45.37 · 9552.08%
- Op Income
- $-45,895,000
- FCF YoY
- 96.52%
Performance & Tape
- 52W High
- $21.95
- 52W Low
- $4.85
- 50D MA
- $9.14
- 200D MA
- $8.84
- Beta
- 0.77
- Avg Volume
- 33.23K
Get TickerSpark's AI analysis on FGEN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 31, 22 | Wettig Thane | other | 0 |
Our FGEN Coverage
We haven't published any research on FGEN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FGEN Report →